Pedersen et al., 1989 - Google Patents

Clinical course of primary HIV infection: consequences for subsequent course of infection.

Pedersen et al., 1989

View PDF
Document ID
16336102611941161438
Author
Pedersen C
Lindhardt B
Jensen B
Lauritzen E
Gerstoft J
Dickmeiss E
Gaub J
Scheibel E
Karlsmark T
Publication year
Publication venue
British Medical Journal

External Links

Snippet

OBJECTIVE--To investigate the impact of the clinical course of the primary HIV infection on the subsequent course of the infection. DESIGN--Prospective documenting of seroconversion, follow up at six month intervals, and analysis of disease progression by life …
Continue reading at www.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—AIDS or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Similar Documents

Publication Publication Date Title
Pedersen et al. Clinical course of primary HIV infection: consequences for subsequent course of infection.
Fauci et al. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations
Learmont et al. Long-term symptomless HIV-1 infection in recipients of blood products from a single donor
Blattner et al. Epidemiology of human T-lymphotropic virus type III and the risk of the acquired immunodeficiency syndrome
Tzakis et al. Transplantation in HIV+ patients
Stein et al. CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review
Peterman et al. Transfusion-associated acquired immunodeficiency syndrome in the United States
English et al. Development of clinical disease in cats experimentally infected with feline immunodeficiency virus
Hoffman et al. The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration
Jones et al. AIDS and haemophilia: morbidity and morality in a well defined population.
Weiss How does HIV cause AIDS?
Klaassen et al. Anti‐neutrophil cytoplasmic autoantibodies in patients with symptomatic HIV infection
Madhok et al. Impaired cell mediated immunity in haemophilia in the absence of infection with human immunodeficiency virus.
Bulterys et al. Sexual behavior and injection drug use during pregnancy and vertical transmission of HIV-1
Aiuti et al. IgM and IgG antibodies to human T cell lymphotropic retrovirus (HTLV-III) in lymphadenopathy syndrome and subjects at risk for AIDS in Italy.
Resnick et al. Detection of HTLV-III/LAV-specific IgG and antigen in bronchoalveolar lavage fluid from two patients with lymphocytic interstitial pneumonitis associated with AIDS-related complex
Niu et al. Zidovudine treatment in patients with primary (acute) human immunodeficiency virus type 1 infection: a randomized, double-blind, placebo-controlled trial
Valle Febrile pharyngitis as the primary sign of HIV infection in a cluster of cases linked by sexual contact
Read et al. Elevated levels of interferon-induced 2′–5′ oligoadenylate synthetase in generalized persistent lymphadenopathy and the acquired immunodeficiency syndrome
Pifer et al. Evidence for depressed humoral immunity to Pneumocystis carinii in homosexual males, commercial plasma donors, and patients with acquired immunodeficiency syndrome
Teitel et al. Two‐year evaluation of clinical and laboratory variables of immune function in 117 hemophiliacs seropositive or seronegative for HIV‐1
Drummond Seronegative 18 months after being bitten by a patient with AIDS
Ammann et al. Laboratory investigation of pediatric acquired immunodeficiency syndrome
Biberfeld et al. Transmission of HIV infection to heterosexual partners but not to household contacts of seropositive haemophiliacs
Okonko et al. Serological Prevalence of Hepatitis C Virus among Febrile Patients Attending a General Hospital in Emohua LGA, Rivers State, Nigeria